Cardiometabolic Signatures Drive Divergent HCC Risk Trajectories in MASLD-Associated Advanced Fibrosis
A study of patients with MASLD and advanced fibrosis found that a higher cumulative burden of cardiometabolic risk factors significantly increases the risk of developing hepatocellular carcinoma. The research highlights how specific metabolic profiles correlate with more advanced tumor stages at diagnosis.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognised as a systemic disorder driven by cardiometabolic risk factors (CMRF), including obesity, Type 2 diabetes mellitus (T2DM), hypertension, and dyslipidaemia. 1-3 While advanced fibrosis (AF) is a major determinant of hepatocellular carcinoma (HCC) risk, the impact of cumulative metabolic burden and specific CMRF combinations on HCC trajectories remains unclear. 2,3 This study aimed to evaluate how distinct metabolic profiles influence HCC risk in patients with MASLD with AF.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in